Match Document Document Title
9261498 Biomarker for sensitivity to mTOR inhibitor therapy in kidney cancer  
The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits...
9261497 Method of treating cancer with modulators of SCFSkp2  
The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating cancer...
9260519 Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer  
Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and/or invasion of a cancer cell in the subject, comprising administering to the subject...
9260513 Pharmaceutical composition for treatment and/or prevention of cancer  
This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer....
9259484 Methods for treating cancer using an immunotoxin  
The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on...
9259468 Cancer therapy via selective uptake of specialized nanoparticles in cancer cells  
Disclosed herein are polymer/fullerene nanoparticles that have selective uptake into cancer cells, and which, upon being taken into the cancer cells induce apoptosis. Induction of apoptosis can be...
9259399 Targeting CDK4 and CDK6 in cancer therapy  
The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and/or CDK6 inhibits cell...
9255927 Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics  
Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at...
9255925 ELISA detection of urine DEK to predict and diagnose bladder cancer in humans  
The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as...
9255297 CHK2 polymorphism as a cancer marker  
The invention relates to the use of gene modifications in the human gene CHK2 (CHEK2), which encodes the checkpoint kinase 2, for predicting the risk and progression of cancer diseases, for...
9255155 Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer  
The present disclosure relates to antibodies specific for urokinase-type plasminogen activator (uPA). According to certain embodiments, the anti-uPA antibody specifically binds to the active form...
9255139 Tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI)-anchors for treatment of cancer and skin lesions  
The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)-anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in...
9255116 Multimeric dual-modality breast cancer diagnostic agents  
The present invention describes dual-modality probes. In particular, the present invention discloses hydroxyapatite specific multimeric bisphosphonate dual-modality MRI and optical probes.
9254309 Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation  
A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising...
9254308 Kits and methods for the treatment of cancer using gliadin peptides  
Kits and methods for treating cancer comprising administration of a gliadin peptide to a patient are disclosed herein. A kit according to the invention comprises a pharmaceutical composition...
9254299 Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer  
Cancer can be treated by administration of TH-302 in combination with a Chk1 inhibitor.
9254293 Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH  
This invention provides methods of treating androgenetic alopecia (AGA), acne, rosacea, prostate cancer, and benign prostatic hypertrophy (BPH), comprising the step of contacting a subject with a...
9254120 Method for predicting breast cancer patient response to combination therapy  
A mass-spectral method is disclosed for determining whether breast cancer patient is likely to benefit from a combination treatment in the form of administration of a targeted anti-cancer drug in...
9250243 Drug selection for lung cancer therapy using antibody-based arrays  
The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of...
9249469 Complex sets of miRNAs as non-invasive biomarkers for colon cancer  
The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject. Further, the present invention relates...
9249468 Methods and materials related to ovarian cancer  
Described herein are methods for diagnosing ovarian cancer. In particular, certain microRNAs are useful to the response to chemotherapy of ovarian cancer patients.
9249467 Bladder cancer detection composition, kit and associated methods  
Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of bladder cancer in a subject are provided by detecting in a urine sample a combination of biomarkers. In one...
9249466 Methods and compositions for treating cancer  
We describe a method of determining whether a cancer cell is likely to be resistant to treatment by an mTOR inhibitor. The method may comprise detecting PPP2R2B (GenBank Accession Number:...
9249409 Method for detection of cancer  
A method for detecting a cancer(s) based on an expression of prescribed polypeptides is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine...
9249223 Humanized anti CXCR4 antibodies for the treatment of cancer  
The present invention relates to a novel isolated humanized antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational...
9249128 Anti-cancer serine hydrolase inhibitory carbamates  
Serine hydrolases are implicated in malconditions such as cancer, central nervous system disorders, cardiovascular disorders, obesity, and metabolic disorders. Many serine hydrolases expressed in...
9248200 Method of delivering an anti-cancer agent to a cell  
There is provided a delivery vehicle comprising an anti-cancer agent together with a conjugate of a delivery agent containing a free aldehyde and a flavonoid, having the delivery agent conjugated...
9248163 Insulin-like growth factor binding protein 7 for treatment of cancer  
Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an IGFBP7 agent...
9248156 Use of extracts or materials extracted from Piper cubeba L. as an effective component in a drug for the treatment of cancer diseases  
The present invention is directed to the use of extracts or of extract compounds from Piper cubeba L. as active components in a medicament for the treatment of cancer. The invention also relates...
9248124 Use of inhibitors of IκB kinase for the treatment of cancer  
The present invention provides inhibitors of IκB kinase of general formula (I). or a stereoisomer or physiologically tolerable salt thereof, for use in the inhibition of the growth of a multiple...
9248114 Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ  
The present invention refers to the use of a compound of Formula (I′) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological...
9248110 Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis  
Compositions and methods for treating and preventing cancer, particularly lung cancer, lymphangioleiomyomatosis and asthma are provided.
9244075 Compositions and methods for detecting, diagnosing, and treating cancer  
The present invention provides compositions and methods useful for diagnosing, treating, and preventing cancer, particularly ovarian cancer and uterine cancer, based on the discovery that the...
9244058 Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors  
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for...
9243296 Compositions and methods for prognosis and treatment of prostate cancer  
Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of...
9243048 Decreasing cancer cell proliferation with WNT remaining active  
The genes the expression of which is reduced or disappeared in immortal cells including cancer cells are isolated, their DNA sequences are determined, the genes are expressed to produce cell...
9242041 Method and apparatus for cancer treatment  
An apparatus for treating solid tumors having at least one hollow needle having at least one perforation, at least one ground electrode, a pump for delivering a chemotherapeutic agent through the...
9242012 Methods for killing PSMA-expressing, taxane-resistant cancer cells  
Methods of killing prostate-specific membrane antigen (PSMA)-expressing, taxane-resistant cancer cells are provided. In particular, PSMA-expressing, taxane-resistant cancer cells are contacted...
9241998 Methods and compositions for treatment of cancer using oncolytic RSV activity  
The present invention relates generally to methods and compositions employing the oncolytic activity of respiratory syncytial virus (RSV) to treat cancer and other neoplastic disorders.
9241949 Compositions and methods for treating cancer  
A method of one or more of, inhibiting motility, migration, dispersal, and metastasis of a cell that expresses an RPTP, which is proteolytically cleaved to form intracellular fragments in the cell...
9241920 Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression  
The present invention is directed to methods of inhibiting cancer cell proliferation, differentiation and/or survival. These methods involve the administration of Fbw7 E3 ligase inhibitors to...
9238682 Anti-cancer therapeutic strategy to overcome cancer resistance and to enable tailoring treatment to patients  
A gene construct comprising a programmed-cell-death executioner gene having a nuclear localization signal, a deleted signal peptide, an inhibitor-resistant binding site, a promoter, and an...
9238677 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders  
The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a...
9238659 Method of using binuclear gold (I) compounds for cancer treatment  
Provided herein is a method of treating cancer by the administration of binuclear gold(I) compounds in patients in need thereof. The pharmaceutical compounds possess anti-cancer activity such as...
9238645 ITE for cancer intervention and eradication  
A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active...
9238084 Anti-mucin antibodies for early detection and treatment of pancreatic cancer  
Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show...
9238069 Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment  
Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with a death receptor ligand, which method comprises contacting the cancer cells with a death receptor...
9238064 Allogeneic cancer cell-based immunotherapy  
Cell-based immunotherapy (e.g., immunization or vaccination) may be improved by frequent administration to a human subject of allogeneic cancer cells secreting a modified heat shock protein (e.g.,...
9238040 Chemoprevention of colorectal cancer by mesalamine/sulfasalazine  
A method for preventing colorectal cancer in a patient possessing human tropomyocin isoform TC22 is disclosed. The method comprises: (a) detecting a serum protein concentration of TC22 in a...
9238022 Xanthanodien for the treatment of cancer  
The present invention relates to a method for the treatment or prophylaxis of a disease associated with hyperproliferative cellular division, comprising administering to a subject in need thereof...